86 related articles for article (PubMed ID: 22436519)
1. Calculating prescription doses for new sources by biologically effective dose matching.
Pritz J; Forster KM; Saini AS; Biagioli MC; Zhang GG
Brachytherapy; 2012; 11(6):521-7. PubMed ID: 22436519
[TBL] [Abstract][Full Text] [Related]
2. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives.
Chen Z; Nath R
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):825-34. PubMed ID: 12573770
[TBL] [Abstract][Full Text] [Related]
3. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
[TBL] [Abstract][Full Text] [Related]
4. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
5. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
6. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
7. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intraoperatively built custom linked seeds versus loose seed gun applicator technique using real-time intraoperative planning for permanent prostate brachytherapy.
Zauls AJ; Ashenafi MS; Onicescu G; Clarke HS; Marshall DT
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1010-6. PubMed ID: 20888132
[TBL] [Abstract][Full Text] [Related]
9. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes.
Mangili P; Stea L; Cattani F; Lappi S; Giglioli F; Calamia E; Ziglio F; Martinelli R; Longobardi B
Radiother Oncol; 2004 Apr; 71(1):13-21. PubMed ID: 15066291
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy.
Sahgal A; Jabbari S; Chen J; Pickett B; Roach M; Weinberg V; Hsu IC; Pouliot J
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):247-54. PubMed ID: 18722275
[TBL] [Abstract][Full Text] [Related]
12. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
13. Calculated microdosimetric characteristics of 125I and 103Pd brachytherapy seeds at different depths in water.
Wuu CS; Chen J
Radiat Prot Dosimetry; 2006; 122(1-4):506-8. PubMed ID: 17189276
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric and volumetric criteria for selecting a source activity and a source type ((125)I or (103)Pd) in the presence of irregular seed placement in permanent prostate implants.
Wuu CS; Ennis RD; Schiff PB; Lee EK; Zaider M
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):815-20. PubMed ID: 10837969
[TBL] [Abstract][Full Text] [Related]
15. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
16. Focal prostate brachytherapy with (103)Pd seeds.
Butler WM; Merrick GS
Phys Med; 2016 Mar; 32(3):459-64. PubMed ID: 27053451
[TBL] [Abstract][Full Text] [Related]
17. BEDVH-A method for evaluating biologically effective dose volume histograms: application to eye plaque brachytherapy implants.
Gagne NL; Leonard KL; Huber KE; Mignano JE; Duker JS; Laver NV; Rivard MJ
Med Phys; 2012 Feb; 39(2):976-83. PubMed ID: 22320806
[TBL] [Abstract][Full Text] [Related]
18. Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
Krishnamurthy D; Weinberg V; Cunha JA; Hsu IC; Pouliot J
Brachytherapy; 2011; 10(6):461-5. PubMed ID: 21397569
[TBL] [Abstract][Full Text] [Related]
19. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
Gagne NL; Leonard KL; Rivard MJ
Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
[TBL] [Abstract][Full Text] [Related]
20. Treatment planning consideration for prostate implants with the new linear RadioCoil 103Pd brachytherapy source.
Meigooni AS; Awan SB; Rachabatthula V; Koona RA
J Appl Clin Med Phys; 2005; 6(3):23-36. PubMed ID: 16143789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
